Evidence map›Paper›PMID 37261217›Full record

ArticleJournal of diabetes research2023

Astragaloside IV Attenuates High-Glucose-Induced Impairment in Diabetic Nephropathy by Increasing Klotho Expression via the NF-

Jiaxin He, Jialin Cui, Yimin Shi, Tao Wang, Junyan Xin, Yimeng Li, Xiaomeng Shan, Zhiyao Zhu, Yanbin Gao

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. [Potential of early diagnosis and targeted therapy for Klotho protein in chronic kidney disease].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Research Progress of Pyroptosis in Diabetic Kidney Disease.International journal of molecular sciences · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jiaxin HeDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0006-1873-5795
Jialin CuiDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Yimin ShiDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Tao WangDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-6924-0166
Junyan XinDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Yimeng LiDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
Xiaomeng ShanDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-1946-7631
Zhiyao ZhuDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0001-8030-5450
Yanbin GaoDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-9547-5652
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Deficiencies in klotho are implicated in various kidney dysfunctions including diabetic nephropathy (DN) related to inflammatory responses. Klotho is closely related to inflammatory responses and is a potential target for ameliorating kidney failure. Pyroptosis, an inflammatory form of programmed cell death, is reported to take part in DN pathogenesis recently. This study is aimed at exploring whether and how klotho inhibited podocyte pyroptosis and whether astragaloside IV (AS-IV) protect podocyte through the regulation of klotho. Materials and Methods: SD rat model of DN and conditionally immortalized mouse podocytes exposed to high glucose were treated with AS-IV. Biochemical assays and morphological examination, cell viability assay, cell transfection, phalloidin staining, ELISA, LDH release assay, SOD and MDA detection, MMP assay, ROS level detection, flow cytometry analysis, TUNEL staining assay, PI/Hoechst 33342 staining, immunofluorescence assay, and western blot were performed to elucidate podocyte pyroptosis and to observe the renal morphology. Results: The treatment of AS-IV can improve renal function and protect podocytes exposed to high glucose. Klotho was decreased, and AS-IV increased klotho levels in serum and kidney tissue of DN rats as well as podocytes exposed to high glucose. AS-IV can inhibit DN glomeruli pyroptosis Conclusion: Altogether, our results demonstrate that the protective effect of AS-IV in upregulating klotho expression in diabetes-induced podocyte injury is associated with the inhibition of NLRP3-mediated pyroptosis via the NF-

Indexed as

Diabetes MellitusDiabetic NephropathiesPodocytesAnimalsGlucoseInflammasomesMiceNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinRatsRats, Sprague-DawleyReactive Oxygen SpeciesSaponinsTriterpenesastragaloside AGlucoseInflammasomesNF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseNlrp3 protein, ratReactive Oxygen SpeciesSaponinsTriterpenes

Identifiers

PMID37261217
PMCPMC10228232
OpenAlexW4377232560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.